Dccr
Obesity Associated With PCSK1 Mutation (rs6232 Variant)
Soleno Therapeutics, Inc.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Obesity Associated With PCSK1 Mutation (rs6232 Variant) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Setmelanotide Rhythm Pharmaceuticals, Inc. | Phase 3 | BB |
lb54640 LG Chem | Phase 2 | CCC |
Same molecule, other indications
Dccr is also rated in:
severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiencyDormant
CCC
Indicative ·
53 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →